169322 ⎘
Investigating or analysing materials by specific methods not covered by groups -; Biological material, e.g. blood, urine ; Haemocytometers; Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids; Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors Interferon
CD11B AGONISTS FOR TREATMENT OF AUTOIMMUNE DISEASE
#2MYCOBACTERIUM TUBERCULOSIS PROTEINS IN DIAGNOSTIC ASSAYS AND DEVICES FOR TUBERCULOSIS DETECTION AND DIAGNOSIS
#3DEXAMETHASONE FOR TREATING AUTISM
#4SINGLE CELL SECRETOME ANALYSIS
#5IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
#6USE OF EMAPALUMAB FOR TREATMENT
#7CHEMICAL SCREEN OF MODULATORS FOR VACCINE ADJUVANTS
#8PHOSPHATIDYLSERINE TARGETING MOLECULE COMBINED WITH MEMORY T CELL ANTIGEN FOR THERAPEUTIC, DIAGNOSTIC AND ADJUVANT USE
#9METHODS FOR PREDICTING EFFICACY OF A MODIFIED LIVE PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) VACCINE
#10FUNCTIONAL ASSAY FOR QUICKLY DETERMINING IMMUNE STATUS
#11METHOD OF CHARACTERIZING TUMORS
#12SIGNATURES AND DETERMINANTS FOR DIAGNOSING INFECTIONS AND METHODS OF USE THEREOF
#13METHODS AND MATERIALS FOR THE DETECTION OF LATENT TUBERCULOSIS INFECTION
#14USE OF AMINO ACID SEQUENCES FROM MYCOBACTERIUM TUBERCULOSIS OR CORRESPONDING NUCLEIC ACIDS FOR DIAGNOSIS AND PREVENTION OF TUBERCULAR INFECTION, DIAGNOSTIC KIT AND VACCINE THEREFROM
#15METHODS FOR TREATING BLADDER CANCER
#16CRISPR/CAS-Associated Detection Assays, Methods and Kits
#17MINIMALLY-INVASIVE MEASUREMENT OF ESOPHAGEAL INFLAMMATION
#18COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNITY, INCLUDING AUTOIMMUNITY ASSOCIATED WITH CANCER AND CANCER THERAPY
#19METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS
#20METHOD FOR PREDICTING THE OFF-TARGET BINDING OF A PEPTIDE WHICH BINDS TO A TARGET PEPTIDE PRESENTED BY A MAJOR HISTOCOMPATIBILITY COMPLEX
#21INFORMATION PROVISION METHOD FOR EXAMINING ACTIVE IMMUNITY BY USING PRODUCTION OF NEUTRALIZING ANTIBODIES AND INTERFERON GAMMA
#22BIOMARKERS PREDICTIVE OF CYTOKINE RELEASE SYNDROME
#23Patient Profiling for Antigen-Specific Immunomodulatory Therapies
#24AGENT FOR INDUCING INTERFERON PRODUCTION CONTAINING LACTIC ACID BACTERIA
#25METHODS FOR DETERMINING TUMOR IMMUNE STATUS
#26NEW TREATMENT AND PREVENTION BASED ON NEW METHOD FOR CONTROLLING CELLULAR IMMUNITY
#27STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY
#28METHODS AND COMPOSITIONS RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY
#29METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS
#30COMPOSITIONS AND METHODS FOR DIAGNOSING SARS-COV-2 (COVID-19) AND FOR MONITORING SARS-COV-2-SPECIFIC IMMUNOLOGICAL MEMORY
#31EARLY CANCER DIAGNOSIS METHOD AND DIAGNOSTIC KIT USING INTERFERON GAMMA GENE CONCENTRATION MEASUREMENT IN EXOSOMES
#32METHODS FOR TREATING MULTIPLE MYELOMA AND THE USE OF COMPANION BIOMARKERS FOR 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE
#33KIT FOR QUANTITATIVE DETECTION USING FLUORESCENT MICROARRAY
#34BIOMARKERS FOR VITILIGO
#35METHODS OF ISOLATING T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION
#36METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-ASSOCIATED INFECTION IN A PATIENT
#37PROPROTEINS AND METHODS OF USE THEREOF
#38METHODS FOR IDENTIFYING PATTERNS OF IFN INDUCED EXPRESSION AND USE IN DIAGNOSIS, MONITORING AND THERAPY
#39PROPROTEINS AND METHODS OF USE THEREOF
#40METHOD FOR DIAGNOSING AND TREATING FIBROMYALGIA
#41SYSTEMS AND METHODS FOR EVALUATING NK CELLS
#42HER3 PULSED DC1 THERAPY
#43COMPOSITE BIOMARKER FOR CANCER THERAPY
#44METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS
#45IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
#46Therapeutically Triggering an Innate Immune Response in a Target Tissue
#47METHOD OF DIAGNOSING CANCER AND DIAGNOSIS KIT USING MEASUREMENT OF NK CELL ACTIVITY
#48SINGLE CELL SECRETOME ANALYSIS
#49IFNbeta as a Pharmacodynamic Marker in VSV-IFNbeta-NIS Oncolytic Therapy
#50IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
#51METHOD FOR TREATING ATOPIC DERMATITIS USING MONOCLONAL STEM CELLS
#52COMPOSITIONS AND METHODS FOR ENHANCING MUCOSAL IMMUNITY
#53NOVEL ANTI-IFNAR1 ANTIBODIES
#54Use of amino acid sequences from or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
#55Agent for inducing interferon production containing lactic acid bacteria
#56IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
#57COMPOSITIONS AND METHODS RELATING TO C5L2
#58USE OF PERIPHERAL BLOOD PRO- AND ANTI-INFLAMMATORY CYTOKINE RATIOS AS MARKERS OF IMPLANTATION PRECEDING PREGNANCY
#59BIOMARKERS
#60Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer
#61Signatures and determinants for diagnosing infections and methods of use thereof
#62Tuberculosis diagnosis method and apparatus therefor
#63METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
#64COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
#65DIAGNOSTIC BLOOD TEST FOR SARCOIDOSIS
#66IFN-GAMMA-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF
#67METHODS OF DETERMINING INTERFERON HAVING DIRECT INHIBITORY EFFECTS ON TUMORS AND USES THEREOF
#68METHODS AND KITS FOR DETECTING MISFOLDED PROTEINS
#69Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex
#70Human anti-IFN-α antibodies
#71Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
#72METHODS AND MATERIALS FOR THE DETECTION OF LATENT TUBERCULOSIS INFECTION
#73COMPOSITIONS AND METHODS RELATED TO INNATE RESPONSE TO DNA AND REGULATION OF INTERFERON-BETA
#74METHOD FOR MEASURING SYSTEMIC CHRONIC INFLAMMAGING
#75Method and platform for detecting immunogenicity of tumor neoantigen
#76METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF SEPSIS
#77IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF
#78STING levels as a biomarker for cancer immunotherapy
#79SURFACE FUNCTIONALISED MATERIALS FOR SAMPLING BIOLOGICAL MOLECULES
#80QUANTITATIVE BIOMARKERS OF EHV-1 SUSCEPTIBILITY AND PROTECTION
#81Use of amino acid sequences from or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
#82Compositions comprising gamma 9 delta 2 T-cell receptors and methods of use thereof to treat cancer
#83Minimally-invasive measurement of esophageal inflammation
#84Biomarkers for vitiligo
#85ANTI-ILT7 ANTIBODY
#86PROPROTEINS AND METHODS OF USE THEREOF
#87Biomarkers related to organ function
#88IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
#89DOSE DETERMINATION FOR IMMUNOTHERAPEUTIC AGENTS
#90DOSAGE OF A GLUTEN PEPTIDE COMPOSITION
#91PEPTIDES FOR USE IN TREATMENT AND DIAGNOSIS OF TYPE 1 DIABETES
#92Signatures and determinants for diagnosing infections and methods of use thereof
#93METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION
#94COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
#95COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
#96Use of amino acid sequences from or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
#97Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
#98IFN-gamma-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof
#99MYCOBACTERIUM TUBERCULOSIS PROTEINS IN DIAGNOSTIC ASSAYS AND DEVICES FOR TUBERCULOSIS DETECTION AND DIAGNOSIS
#100Methods and compositions related to toxicity associated with cell therapy
#101METHODS OF TREATING CANCER IN A SUBJECT BY ADMINISTERING A COMPOSITION COMPRISING GAMMA 9 DELTA 2 T-CELL RECEPTORS
#102IFN-γ-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof
#103PREDICTIVE BIOMARKERS OF CLINICAL RESPONSE TO ANTI-LPS IMMUNOGLOBULIN TREATMENT
#104COMPOSITIONS AND METHODS RELATING TO C5L2
#105Agent for inducing interferon production containing lactic acid bacteria
#106Screening assay for choice of prebiotic to prevent/treat gastrointestinal and systemic diseases
#107CXCR4 receptor-binding compounds useful for increasing interferon level
#108COMPOSITIONS, KITS AND METHODS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS
#109COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
#110Therapeutically triggering an innate immune response in a target tissue
#111BIOMARKERS
#112Human anti-IFN-α antibodies
#113Early Diagnosis of Autoimmune and Inflammatory Disorders
#114Collapsible element pocket former
#115Collapsible element pocket former
#116Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
#117Method for diagnosing and treating fibromyalgia
#118Minimally-invasive measurement of esophageal inflammation
#119IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF
#120DEVELOPMENT OF PROGNOSTIC MARKERS DSG-3 FROM THE SALIVA OF ORAL CANCER PATIENTS
#121METHODS AND MATERIALS FOR TREATING AUTOIMMUNE CONDITIONS
#122RISK STRATIFICATION IN INFLUENZA
#123Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
#124DETERMINATION OF FAVORABLE DATE(S) FOR THERAPEUTIC TREATMENT DELIVERY
#125Biomarkers for assessing subjects with multiple sclerosis
#126IDENTIFICATION OF PATIENTS IN NEED OF PD-L-1 INHIBITOR COTHERAPY
#127Methods for identifying patterns of IFN induced expression and use in diagnosis, monitoring and therapy
#128Biomarkers predictive of cytokine release syndrome
#129Methods for increasing levels of interferon activity with an interferon lambda 3 polypeptide
#130Use of amino acid sequences from or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
#131BIOMARKERS FOR PREDICTING A RESPONSE TO AN IMMUNOMODULATING TREATMENT IN PATIENTS WITH INFLAMMATORY DISEASE
#132Early determination of pregnancy status in ruminants
#133Diagnostic blood test for sarcoidosis
#134Methods of treating cancer in a subject by administering a composition comprising gamma 9 delta 2 T-cell receptors
#135Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
#136Autoantigens for diagnosis of rheumatoid arthritis
#137Methods for Monitoring Responsiveness to Anti-SMAD7 Therapy
#138NOVEL DESIGN OF ENZYME-LINKED IMMUNOSORBENT ASSAY PLATES AND SYSTEMS AND METHODS OF USE THEREOF
#139PRE-SYMPTOMATIC DIAGNOSIS OF A VIRAL ILLNESS
#140Predictive biomarkers of clinical response to anti-LPS immunoglobulin treatment
#141Polymeric Fc proteins and methods of screening to alter their functional characteristics
#142Methods and kits for detecting misfolded proteins
#143Engineered Dendritic Cells and Uses for the Treatment of Cancer
#144METHOD FOR ENHANCING IMMUNE CELL FUNCTION AND METHOD FOR ASSESSING IMMUNE CELL MULTIFUNCTIONALITY
#145METHODS OF IDENTIFYING ANTIGENS FOR VACCINES
#146Cleavage-activatable interferon-alpha proprotein
#147proteins
#148METHOD FOR ENHANCING IMMUNE CELL FUNCTION AND METHOD FOR ASSESSING IMMUNE CELL MULTIFUNCTIONALITY
#149METHODS FOR PREDICTING CLINICAL OUTCOMES IN SUBJECTS AFFLICTED WITH ULCERATIVE COLITIS
#150METHODS OF ISOLATING T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION
#151Screening assay for choice of prebiotic to prevent/treat gastrointestinal and systemic diseases
#152Nucleic acid molecules encoding combinatorial gamma 9 delta 2 T-cell receptors and methods of use thereof to treat cancer
#153Plasmonic substrates for metal-enhanced fluorescence based sensing, imaging and assays for cells
#154COMPOSITIONS, KITS AND METHODS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS
#155Epitope recognized by anti-interferon gamma autoantibodies in patients with disseminated mycobacterial infections and the application therefor
#156Agent for inducing interferon production containing lactic acid bacteria
#157Early Diagnosis of Autoimmune and Inflammatory Disorders
#158Minimally-invasive measurement of esophageal inflammation
#159METHODS FOR DIAGNOSIS AND PROGNOSIS OF INFLAMMATORY BOWEL DISEASE USING CYTOKINE PROFILES
#160Human anti-IFN-α antibodies
#161Signatures and determinants for diagnosing infections and methods of use thereof
#162Eye disease treatment agent, screening method therefor, and method for predicting rejection response associated with retinal pigment epithelial cell transplant
#163Polymer particles and uses thereof
#164Compositions and methods for modulating an immune response
#165SUPERANTIGEN POST-EXPOSURE THERAPY
#166IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
#167METHODS OF T CELL EPITOPE PROFILING, MAKING T CELL COMPOSITIONS, AND TREATING DISEASES
#168Method for determining site having N-linked sugar chain added thereto or proportion of said addition
#169Interferon-gamma release assays for diagnosis of invasive fungal infections
#170METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
#171Methods for inhibiting HIV or HCV infection by administering TIM-3 binding inhibitors
#172CONDUCTIVE HYDROGELS FOR AFFINITY SENSING
#173METHODS FOR DIAGNOSING, SCREENING, IDENTIFYING, MONITORING, AND TREATING ADVERSE LOCAL TISSUE REACTIONS, WHICH LEAD TO FAILURE OF ORTHOPEDIC IMPLANTS
#174COMPOSITIONS AND METHODS RELATING TO C5L2
#175Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
#176Biomarkers related to organ function
#177Method for increasing interferon activity in an individual
#178Dosage of a gluten peptide composition
#179Diagnostic blood test for sarcoidosis
#180Interferon lambda-antibody complexes
#181Methods and kits for detecting misfolded proteins
#182PERSONALISED MEDICINE
#183Diagnostic biomarker to predict women at risk for preterm delivery
#184Nanoelectronic-enzyme linked immunosorbent assay system and method
#185Parasitic biological agents for treatment and prevention of graft versus host disease
#186B7-H4 fusion proteins and methods of use thereof
#187PROCESS FOR THE MEASUREMENT OF THE POTENCY OF GLATIRAMER ACETATE
#188Method for identifying biologically active oligonucleotides capable of modulating the immune system
#189BIOMARKERS FOR INFLAMMATORY DISEASE AND METHODS OF USING SAME
#190Method for Differentiating Sepsis and Systemic Inflammatory Response Syndrome (SIRS)
#191METHODS FOR MONITORING CD4+ T-HELPER TYPE 1 RESPONSE IN CANCER AND IMMUNE RESTORATION
#192Risk stratification in influenza
#193METHOD FOR ANALYZING MOLECULE USING THERMOPHORESIS
#194Use of amino acid sequences from or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
#195Salivary inflammatory biomarkers associated with glycemic control and oral health
#196Method for diagnosing fibromyalgia
#197METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF SEPSIS
#198COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF MALIGNANT GLIOMAS
#199Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex
#200Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
#201USE OF POST-TRANSCRIPTIONAL GENE SILENCING FOR IDENTIFYING NUCLEIC ACID SEQUENCES THAT MODULATE THE FUNCTION OF A CELL
#202Soluble notch receptor proproteins and methods of use thereof
#203BIOMARKERS FOR DIAGNOSING AND/OR MONITORING TUBERCULOSIS
#204Diagnostic blood test for sarcoidosis
#205Methods For Determining Anti-TNF Therapeutic Response
#206Detection, capture and quantification of biological moieties from unprocessed bodily fluids using nanoplasmonic platform
#207Status of Tuberculosis Infection in an Individual
#208Methods of monitoring responsiveness to anti-SMAD7 therapy
#209Early determination of pregnancy status in ruminants
#210Genetically modified non-human animals and methods relating to innate immune system response detection
#211Biomarkers
#212In-vitro process for the quick determination of a patient's status relating to infection with
#213Method for monitoring HIV specific T cell responses
#214Kit for monitoring immune status after transplant and method for monitoring immune status using same
#215Gamma 9 delta 2 T cell receptors
#216Signatures and determinants for diagnosing infections and methods of use thereof
#217Soluble ST2 as a marker for risk of mortality in HIV-infected subjects
#218METHOD FOR DIAGNOSING AND TREATING FIBROMYALGIA
#219Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
#220Agent for inducing interferon production containing lactic acid bacteria
#221MICROFLUIDIC ASSAY DEVICES AND METHODS
#222METHODS AND COMPOSITIONS FOR DETECTING IMMUNE RESPONSES
#223Methods for diagnosing degenerative joint disease
#224Induced intercellular communication
#225Methods for treatment of age-related macular degeneration
#226Assay method for peptide specific T-cells
#227Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity
#228USING A CYTOKINE SIGNATURE TO DIAGNOSE DISEASE OR INFECTION
#229METHODS FOR DIAGNOSIS AND PROGNOSIS OF INFLAMMATORY BOWEL DISEASE USING CYTOKINE PROFILES
#230AGENT FOR INDUCING INTERFERON PRODUCTION CONTAINING LACTIC ACID BACTERIA
#231Method for diagnosing Lyme disease using a cellular immunological test
#232Method for identifying biologically active oligonucleotides capable of modulating the immune system
#233Function homology screening
#234INTERFERON GENE SIGNATURE AND METHODS OF USE THEREOF
#235Use of amino acid sequences from mycobacterium tuberculosis or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
#236MARKERS OF VULNERABILITY OF THE ATHEROSCLEROSIS PLAQUE
#237Multiplex Immune Effector Molecule Assay
#238Method for diagnosing Q-fever using a cellular immunological test
#239SOLUBLE ST2 AS A MARKER FOR DISEASE
#240Engineered dendritic cells and uses for the treatment of cancer
#241Method for real-time measurement of the individual secretions of a cell
#242Interferon lambada-antibody complexes
#243PROCESS FOR THE MEASUREMENT OF THE POTENCY OF GLATIRAMER ACETATE
#244Monkey homolog of human interferon omega
#245B7-H4 fusion proteins and methods of use thereof
#246Anti-interferon-α antibodies
#247Method and kit for measuring component in the presence of fatty acid alkanolamide or nonionic polyoxyethylene surfactant
#248IFN TYPE-I PRODUCTION INHIBITOR AND METHOD FOR SCREENING FOR SAME
#249Methods and compositions for the inhibition of transplant rejection
#250T-Bet Compositions and Methods of Use Thereof
#251INTERFERON-LIKE PROTEINS AND USES THEREOF
#252Anti-ILT7 antibody
#253COMPOSITIONS, KITS AND METHODS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS
#254Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
#255Biomarker for treating cancer patients
#256Engineered Dendritic Cells and Uses for the Treatment of Cancer
#257Interferon-lambda 1 polypeptides
#258THERAPEUTICS FOR AGE-RELATED MACULAR DEGENERATION
#259Sepsis diagnostic test
#260INTERFERON-ALFA SENSITIVITY BIOMARKERS
#261BIOMARKER FOR MONITORING PATIENTS
#262Methods and kits for detecting misfolded proteins
#263ANTI-INTERFERON-ALPHA ANTIBODIES
#264Anti-interferon-α antibodies
#265Process for the measurement of the potency of glatiramer acetate
#266System for the Determination of Molecules Altering the Function of Interferon, Method Therefor and Compounds Altering Interferon Activity
#267IFN-ALPHA/BETA-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION THROUGH A NOVEL LIGAND-RECEPTOR PAIR: IFN- LIGANDS ENGAGE A NOVEL RECEPTOR IFN-RN (CRF2-12) AND IL-10R2 (CRF2-4) FOR SIGNALING ANDINDUCTION OF BIOLOGICAL ACTIVITIES
#268Methods of determining efficacy of treatments of diseases of the bowel
#269MDA-7 PROTEINS AND METHODS OF USE THEREOF
#270Monoclonal antibodies specific for human interferon-alpha subtype alpha 8
#271Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy
#272SYSTEMIC LUPUS ERYTHEMATOSUS
#273Use of PS20/WFDC1 and Interferons to Diagnose, Monitor and Treat Viral Diseases
#274Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
#275Minimally-invasive measurement of esophageal inflammation
#276Protease activatable interferon alpha proprotein
#277Assay method for peptide specific T-cells
#278Nanoelectronic-enzyme linked immunosorbent assay system and method
#279INTERLEUKIN 6 AND TUMOR NECROSIS FACTOR ALPHA AS BIOMARKERS OF JNK INHIBITION
#280Cytokines and Genes Differentially Affected by TNF Blockers
#281METHODS FOR DIAGNOSING HYPERSENSITIVITY REACTIONS
#282Anti-ILT7 antibody
#283Methods for Treating Autoimmune Diseases in a Subject and In Vitro Diagnostic Assays
#284MDA-7 PROTEINS AND METHODS OF USE THEREOF
#285IFN-λ polypeptides and compositions
#286Methods for determining anti-TNF therapeutic response
#287Engineered Dendritic Cells and Uses for the Treatment of Cancer
#288Process for the measurement of the potency of glatiramer acetate
#289Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
#290Methods and compositions for detecting immune responses
#291Diagnostic test
#292T-bet compositions and methods of use thereof
#293Method for diagnosing and treating acute joint injury
#294Method for the quantitative determination of poloxamers
#295METHODS AND COMPOSITIONS FOR ASSESSING IL-12 OR THE NEUTRALIZATION OF IL-12 IN A SAMPLE
#296MONOCLONAL ANTIBODIES TO TYPE I INTERFERON RECEPTOR
#297FUNCTION HOMOLOGY SCREENING
#298FUNCTION HOMOLOGY SCREENING
#299BIOMAP ANALYSIS
#300Methods for recommending a program to improve or maintain pro-inflammatory immune health